Bariatric surgery, lipoprotein metabolism and cardiovascular risk

Current Opinion in Lipidology

Volumn 26, Issue 4, 2015, Pages 317-324

  Tailleux, Anne ^a,b,c,d   Rouskas, Konstantinos ^e   Pattou, François ^a,b   Staels, Bart ^a,b,c,d  

^a France   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

^e BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

Bariatric surgery; bile acids; cardiovascular risk and events; Roux en Y gastric bypass

Indexed keywords

GASTROINTESTINAL HORMONE; LIPOPROTEIN;

BILE ACID METABOLISM; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DYSLIPIDEMIA; FEEDING BEHAVIOR; FOLLOW UP; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; INTESTINE FLORA; LIPID ABSORPTION; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REVIEW; ROUX EN Y GASTRIC BYPASS; STOMACH BYPASS; STOMACH POUCH; ANIMAL; BARIATRIC SURGERY; CARDIOVASCULAR DISEASES; COMPLICATION; METABOLISM; RISK FACTOR;

ANIMALS; BARIATRIC SURGERY; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS; RISK FACTORS;

EID: 84941367220     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000197     Document Type: Review

References (78)

1. Vest AR, Heneghan HM, Agarwal S, et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 2012; 98:1763-1777.
2. Poirier P, Cornier M, Mazzone T, et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation 2011; 123:1683-1701.
3. Ricci C, Gaeta M, Rausa E, et al. Early impact of bariatric surgery on type II diabetes, hypertension, and hyperlipidemia: a systematic review, meta-analysis and meta-regression on 6587 patients. Obes Surg 2014; 24:522-528.
4. Ricci C, Gaeta M, Rausa E, et al. Long-term effects of bariatric surgery on type ii diabetes, hypertension and hyperlipidemia: a meta-analysis and metaregression study with 5-year follow-up. Obes Surg 2015; 209:463-467.
5. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122:248-256.
6. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366:1567-1576.
7. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med 2014; 370:2002-2013.
8. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366:1577-1585.
9. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA 2012; 308:1122-1131.
10. Sjö ström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014; 311:2297-2304.
11. Coen PM, Tanner CJ, Helbling NL, et al. Clinical trial demonstrates exercise following bariatric surgery improves insulin sensitivity. J Clin Invest 2015; 125:248-257.
12. Puzziferri N, Roshek TB3, Mayo HG, et al. Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014; 312:934-942.
13. Courcoulas AP, Christian NJ, Belle SH, et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA 2013; 310:2416-2425.
14. Aminian A, Zelisko A, Kirwan JP, et al. Exploring the impact of bariatric surgery on high density lipoprotein. Surg Obes Relat Dis 2015; 11:238-247.
15. Ai M, Otokozawa S, Asztalos BF, et al. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem 2010; 56:967-976.
16. Julve J, Pardina E, Pé rez-Cué llar M, et al. Bariatric surgery in morbidly obese patients improves the atherogenic qualitative properties of the plasma lipoproteins. Atherosclerosis 2014; 234:200-205.
17. Sjö ström CD, Peltonen M, Wedel H, Sjö ström L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36:20-25.
18. Brea A, Puzo J. Nonalcoholic fatty liver disease and cardiovascular risk. Int J Cardiol 2013; 167:1109-1117.
19. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric surgery for nonalcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; CD007340.
20. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the longterm effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137:532-540.
21. Caiazzo R, Lassailly G, Leteurtre E, et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 2014; 260:893-898.
22. Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int JObes (Lond) 2011; 35:971-981.
23. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann Intern Med 2013; 159:758-769.
24. Lee CJ, Clark JM, Asamoah V, et al. Prevalence and characteristics of individuals without diabetes and hypertension who underwent bariatric surgery: lessons learned about metabolically healthy obese. Surg Obes Relat Dis 2015; 11:142-146.
25. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012; 97:2482-2488.
26. Kuk JL, Ardern CI. Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diabetes Care 2009; 32:2297-2299.
27. Goday A, Benaiges D, Parri A, et al. Can bariatric surgery improve cardiovascular risk factors in the metabolically healthy but morbidly obese patient? Surg Obes Relat Dis 2014; 10:871-876.
28. Immonen H, Hannukainen JC, Iozzo P, et al. Effect of bariatric surgery on liver glucose metabolism in morbidly obese diabetic and nondiabetic patients. J Hepatol 2014; 60:377-383.
29. Kwok CS, Pradhan A, Khan MA, et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Cardiol 2014; 173:20-28.
30. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357:753-761.
31. Arterburn DE, Olsen MK, Smith VA, et al. Association between bariatric surgery and long-term survival. JAMA 2015; 313:62-70.
32. Guidry CA, Davies SW, Sawyer RG, et al. Gastric bypass improves survival compared with propensity-matched controls: a cohort study with over 10-year follow-up. Am J Surg 2015; 209:463-467.
33. Sjö ström L. Review of the key results from the Swedish Obese Subjects (SOS) trial: a prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273:219-234.
34. Lutz TA, Bueter M. The physiology underlying Roux-en-Y gastric bypass: a status report. Am J Physiol Regul Integr Comp Physiol 2014; 307:R1275-R1291.
35. Lutz TA, Bueter M. Physiological mechanisms behind Roux-en-Y gastric bypass surgery. Dig Surg 2014; 31:13-24.
36. Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014; 509:183-188.
37. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013; 17:819-837.
38. Saraiva F, Sposito AC. Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol 2014; 13:142.
39. Jimé nez A, Mari A, Casamitjana R, et al. GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes. Diabetes 2014; 63:3372-3377.
40. Umeda LM, Silva EA, Carneiro G, et al. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg 2011; 21:896-901.
41. Seeley RJ, Chambers AP, Sandoval DA. The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab 2015; 21:369-378.
42. Mokadem M, Zechner JF, Margolskee RFET-AL. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol Metab 2014; 3:191-201.
43. Osto E, Doytcheva P, Corteville C, et al. Rapid and body weight-independent improvement of endothelial and HDL function after Roux-en-Y gastric bypass: role of glucagon-like peptide-1. Circulation 2015; 131:871-881.
44. Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care 2013; 36:1859-1864.
45. Jørgensen NB, Dirksen C, Bojsen-Møller KN, et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. J Clin Endocrinol Metab 2015; 100:E396-406.
46. Dutia R, Embrey M, O'Brien CS, et al. Temporal changes in bile acid levels and 12a-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int J Obes (Lond) 2015; 0:0-0.
47. Chennamsetty I, Claudel T, Kostner KM, et al. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol 2012; 32:1220-1227.
48. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145:2594-2603.
49. Wu X, Ge H, Baribault H, et al. Dual actions of fibroblast growth factor 19 on lipid metabolism. J Lipid Res 2013; 54:325-332.
50. Hao Y, Zhou J, Zhou M, et al. Serum levels of fibroblast growth factor 19 are inversely associated with coronary artery disease in Chinese individuals. PLoS One 2013; 8:e72345.
51. Steinert RE, Peterli R, Keller S, et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity (Silver Spring) 2013; 21:E660-E668.
52. Werling M, Vincent RP, Cross GF, et al. Enhanced fasting and postprandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol 2013; 48:1257-1264.
53. Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes (Lond) 2013; 37:1553-1559.
54. De Giorgi S, Campos V, Egli L, et al. Long-term effects of Roux-en-Y gastric bypass on postprandial plasma lipid and bile acids kinetics in female non diabetic subjects: a cross-sectional pilot study. Clin Nutr 2014. [Epub ahead of print]. doi: 10.1016/j.clnu.2014.09.0118.
55. Chambers AP, Smith EP, Begg DP, et al. Regulation of gastric emptying rate and its role in nutrient-induced GLP-1 secretion in rats after vertical sleeve gastrectomy. Am J Physiol Endocrinol Metab 2014; 306:E424-E432.
56. Dirksen C, Jørgensen NB, Bojsen-Møller KN, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes (Lond) 2013; 37:1452-1459.
57. Seyfried F, Lannoo M, Gsell W, et al. Roux-en-Y gastric bypass in mice-surgical technique and characterisation. Obes Surg 2012; 22:1117-1125.
58. Psáder R, Sterczer A, Pápa K, et al. Effect of enteral feeding on gallbladder function in dogs. Acta Vet Hung 2012; 60:211-222.
59. de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab 2013; 17:657-669.
60. Caron S, Verrijken A, Mertens I, et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2011; 31:513-519.
61. Li L, Liu H, Peng J, et al. Farnesoid X receptor up-regulates expression of lipid transfer inhibitor protein in liver cells and mice. Biochem Biophys Res Commun 2013; 441:880-885.
62. Chennamsetty I, Claudel T, Kostner KM, et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest 2011; 121:3724-3734.
63. Pols TWH, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 2011; 14:747-757.
64. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10:167-177.
65. Shaik FB, Prasad DVR, Narala VR. Role of farnesoid X receptor in inflammation and resolution. Inflamm Res 2015; 64:9-20.
66. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, nonalcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385:956-965.
67. Miyazaki-Anzai S, Masuda M, Levi M, et al. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. PLoS One 2014; 9:e108270.
68. Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015; 21:159-165.
69. Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015; 125:386-402.
70. Kohli R, Setchell KD, Kirby M, et al. A surgical model in male obese rats uncovers protective effects of bile acids postbariatric surgery. Endocrinology 2013; 154:2341-2351.
71. Goncalves D, Barataud A, De Vadder F, et al. Bile routing modification reproduces key features of gastric bypass in rat. Ann Surg 2015; 0:0-0.
72. Karlsson F, Tremaroli V, Nielsen J, Bäckhed F. Assessing the human gut microbiota in metabolic diseases. Diabetes 2013; 62:3341-3349.
73. Hartstra AV, Bouter KEC, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care 2015; 38:159-165.
74. Liou AP, Paziuk M, Luevano JJ, et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 2013; 5:178ra41.
75. Kong L, Tap J, Aron-Wisnewsky J, et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr 2013; 98:16-24.
76. Osto M, Abegg K, Bueter M, et al. Roux-en-Y gastric bypass surgery in rats alters gut microbiota profile along the intestine. Physiol Behav 2013; 119:92-96.
77. Sayin SI, Wahlström A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17:225-235.
78. Drosos I, Tavridou A, Kolios G. New aspects on the metabolic role of intestinal microbiota in the development of atherosclerosis. Metabolism 2015; 64:476-481.